Publications by authors named "Ema Pozek"

Claim this Profile
I
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.
Elias K Mai, Uta Bertsch, Ema Pozek, Roland Fenk, Britta Besemer

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma.
Lisa B Leypoldt, Diana Tichy, Britta Besemer, Mathias Hanel, Marc S Raab, Ema Pozek

Future Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin.
Frank G Rücker, Lars Bullinger, Sibylle Cocciardi, Sabrina Skambraks, Tamara J Luck, Ema Pozek

Blood Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Gender-specific differences in bariatric surgery: epidemiology, treatment and results].
Patrick Téoule, Ema Pozek, Thomas Hielscher, Christoph Reißfelder, Christine Stier

Chirurgie (Heidelb)· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.
Lisa B Leypoldt, Diana Tichy, Britta Besemer, Mathias Hänel, Marc S Raab

J Clin Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis